BIOMAT Database Logo BIOMAT Database Logo

The von Hippel-Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform. 2015

F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
CNRS-UMR 6290 (IGDR)-Université Rennes 1-BIOSIT, 2 Avenue du Professeur L Bernard, 35042 Rennes, France.

BACKGROUND The von Hippel-Lindau (VHL) gene encodes two mRNA variants. Variant 1 encodes two protein isoforms, pVHL213 and pVHL160, that have been extensively documented in the literature. Variant 2 is produced by alternative splicing of exon 2 and encodes a pVHL isoform of 172 amino acids with a theoretical molecular weight of 19 kDa (pVHL172), the expression of which has never been demonstrated so far due to the absence of suitable antibodies. METHODS We have generated an anti-pVHL monoclonal antibody (JD-1956) using pVHL172 recombinant protein. We tested the antibody against exogenous or endogenous expressed proteins in different cell lines. We identified the pVHL172 using a silencing RNA strategy. The epitope of the antibody was mapped using a peptide array. RESULTS We efficiently detected the three different isoforms of pVHL in cell lines and tumorigenic tissues by western blotting and immunohistochemistry and confirmed for the first time the endogenous expression of pVHL172. CONCLUSIONS The endogenous expression of the three isoforms and particularly the pVHL172 has never been shown before due to a lack of a highly specific antibody since none of the available commercial antibodies distinguish the three isoforms of pVHL in cells or in both normal and cancerous human tissues. Evidence of pVHL172 expression emphasises the need to further study its implication in renal tumorigenesis and VHL disease.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D016147 Genes, Tumor Suppressor Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible. Antioncogenes,Cancer Suppressor Genes,Emerogenes,Genes, Cancer Suppressor,Genes, Growth Suppressor,Genes, Metastasis Suppressor,Growth Suppressor Genes,Metastasis Suppressor Genes,Tumor Suppressor Genes,Anti-Oncogenes,Genes, Onco-Suppressor,Oncogenes, Recessive,Tumor Suppressing Genes,Anti Oncogenes,Anti-Oncogene,Antioncogene,Cancer Suppressor Gene,Emerogene,Gene, Cancer Suppressor,Gene, Growth Suppressor,Gene, Metastasis Suppressor,Gene, Onco-Suppressor,Gene, Tumor Suppressing,Gene, Tumor Suppressor,Genes, Onco Suppressor,Genes, Tumor Suppressing,Growth Suppressor Gene,Metastasis Suppressor Gene,Onco-Suppressor Gene,Onco-Suppressor Genes,Oncogene, Recessive,Recessive Oncogene,Recessive Oncogenes,Suppressor Gene, Cancer,Suppressor Gene, Growth,Suppressor Gene, Metastasis,Suppressor Genes, Cancer,Suppressor Genes, Growth,Suppressor Genes, Metastasis,Tumor Suppressing Gene,Tumor Suppressor Gene
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051794 Von Hippel-Lindau Tumor Suppressor Protein A ubiquitin-protein ligase that mediates OXYGEN-dependent polyubiquitination of HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. It is inactivated in VON HIPPEL-LINDAU SYNDROME. VHL Tumor Suppressor Protein,Von Hippel Lindau Tumor Suppressor Protein
D020033 Protein Isoforms Different forms of a protein that may be produced from different GENES, or from the same gene by ALTERNATIVE SPLICING. Isoform,Isoforms,Protein Isoform,Protein Splice Variant,Splice Variants, Protein,Protein Splice Variants,Isoform, Protein,Isoforms, Protein,Splice Variant, Protein,Variant, Protein Splice,Variants, Protein Splice

Related Publications

F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.
May 1996, Human molecular genetics,
F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
The multifaceted von Hippel-Lindau tumour suppressor protein.
August 2014, FEBS letters,
F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
Von Hippel-Lindau tumour suppressor gene. Localization of expression by in situ hybridization.
November 1996, The Journal of pathology,
F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
The von Hippel-Lindau tumor suppressor gene.
March 2001, Experimental cell research,
F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
Functions of the von Hippel-Lindau tumour suppressor protein.
June 1998, Journal of internal medicine,
F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
Detailed genetic mapping of the von Hippel-Lindau disease tumour suppressor gene.
February 1993, Journal of medical genetics,
F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
The von Hippel-Lindau tumour suppressor protein: new perspectives.
June 1999, Molecular medicine today,
F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics.
July 2013, European journal of cancer (Oxford, England : 1990),
F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.
July 2015, Scientific reports,
F Chesnel, and P Hascoet, and J P Gagné, and A Couturier, and F Jouan, and G G Poirier, and C Le Goff, and C Vigneau, and Y Danger, and F Verite, and X Le Goff, and Y Arlot-Bonnemains
Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene.
April 1994, Human molecular genetics,
Copied contents to your clipboard!